A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer ; volume:21 ; number:4 ; day:21 ; month:1 ; year:2016 ; pages:773-782 ; date:8.2016
International journal of clinical oncology ; 21, Heft 4 (21.1.2016), 773-782, 8.2016
- Urheber
-
Akaza, Hideyuki
- Beteiligte Personen und Organisationen
-
Uemura, Hirotsugu
Tsukamoto, Taiji
Ozono, Seiichiro
Ogawa, Osamu
Sakai, Hideki
Oya, Mototsugu
Namiki, Mikio
Fukasawa, Satoshi
Yamaguchi, Akito
Uemura, Hiroji
Ohashi, Yasuo
Maeda, Hideki
Saito, Atsushi
Takeda, Kentaro
Naito, Seiji
SpringerLink (Online service)
- DOI
-
10.1007/s10147-016-0952-6
- URN
-
urn:nbn:de:1111-201608024627
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Akaza, Hideyuki
- Uemura, Hirotsugu
- Tsukamoto, Taiji
- Ozono, Seiichiro
- Ogawa, Osamu
- Sakai, Hideki
- Oya, Mototsugu
- Namiki, Mikio
- Fukasawa, Satoshi
- Yamaguchi, Akito
- Uemura, Hiroji
- Ohashi, Yasuo
- Maeda, Hideki
- Saito, Atsushi
- Takeda, Kentaro
- Naito, Seiji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study